Jim Cramer’s 16 Stock Calls, Including NVIDIA, Coterra, and Honeywell

11. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was among Jim Cramer’s recent stock calls on Mad Money. During the lightning round, a caller asked for Cramer’s thoughts on the stock, and he said:

I think Vertex is very strong. I wish I had bought it for the Charitable Trust a long time ago, when we had the CEO on. It was an excellent call, and then I got cold feet. That was a mistake. It’s a good buy.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) develops and commercializes transformative medicines for serious conditions, including cystic fibrosis, sickle cell disease, and acute pain. Hardman Johnston Global Equity Strategy stated the following regarding Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in its fourth quarter 2025 investor letter:

During the quarter we liquidated Corteva Inc., T-Mobile US, Inc. and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). After meetings with FDA, Vertex Pharmaceuticals Inc. does not see a path forward for a broad neuropathic chronic pain label for Journavx. This lowered potential TAM of Journavx in chronic pain. VX-993 (next generation NaV 1.8) phase II data failed to show competitive/significant benefits so VRTX will not pursue this as a monotherapy. Journavx is launching well in acute pain but still early days so stock reacted negatively to chronic pain updates. Outside of pain, all pipeline updates were positive across kidney and diabetes however given the slower ramp of pain we thought there were better opportunities elsewhere in the portfolio and picked Elanco over Vertex.